Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tube vs. foot: which blood delivery keeps samples pristine?

NCT ID NCT07755007

Knowledge-focused Sponsor: Marmara University Pendik Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial asks whether sending blood samples through a pneumatic tube system damages them more than having a person carry them to the lab. It enrolls adults visiting the emergency department who need routine blood draws. Each participant provides two samples from the same draw, one sent by tube and one carried by hand, so the two methods can be compared directly. The study measures the hemolysis index—a sign of red blood cell damage—to see which transport method keeps samples in better condition for accurate testing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pneumatic tube system transport compared with manual personnel transport for blood samples
What this could lead to
If pneumatic tube transport proves safe, hospitals could use it widely to speed up lab results without risking sample quality, improving emergency care efficiency.
What could go wrong
This is a single-center study with a specific tube system, so results may not apply to other hospitals. The outcome is a lab measure, not a direct patient outcome, and the trial is not designed to prove clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 166 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Presenting to the emergency department of Marmara University Pendik Training and Research Hospital * Venous blood draw required for routine clinical care needing two or more yellow-cap (serum separator) tubes * Written informed consent provided by the participant Exclusion Criteria: * Known underlying hemolytic disorder (e.g., hemolytic anemia, sickle cell disease, G6PD deficiency, autoimmune hemolytic anemia, or TTP/HUS) * Macroscopic hemolysis visible in the sample tube immediately after phlebotomy * Age younger than 18 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood specimen collection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Emergencies Hemolysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood specimen collection Diagnostic errors Hemolysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marmara University Pendik Training and Research Hospital

    Istanbul, Pendik, 34899, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.